Abstract
Therapeutic monoclonal antibodies are widely recognized to be a most promising means to treat an increasing number of human diseases, including cancers and autoimmunity. To a large extent, the efficacy of monoclonal antibody treatment is because IgG antibodies have greatly extended persistence in vivo. However, conventional rodent models do not mirror human antibody pharmacokinetics. The key molecule responsible for the extended persistence antibodies is the major histocompatibility complex class I family Fc receptor, FcRn. We describe human FcRn transgenic mouse models and how they can be exploited productively for the preclinical pharmacokinetic evaluation of therapeutic antibodies.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Burnet FM, Freeman M, Jackson AV, Lush D (1941) The production of antibodies. Macmillan and Company Limited, Melbourne
Simister NE, Mostov KE (1989) An Fc receptor structurally related to MHC class I antigens. Nature 337:184–187
Ahouse JJ, Hagerman CL, Mittal P, Gilbert DJ, Copeland NG, Jenkins NA et al (1993) Mouse MHC class I-like Fc receptor encoded outside the MHC. J Immunol 151:6076–6088
Raghavan M, Gastinel LN, Bjorkman PJ (1993) The class I major histocompatibility complex related Fc receptor shows pH-dependent stability differences correlating with immunoglobulin binding and release. Biochemistry 32:8654–8660
Burmeister WP, Gastinel LN, Simister NE, Blum ML, Bjorkman PJ (1994) Crystal structure at 2.2 A resolution of the MHC-related neonatal Fc receptor. Nature 372:336–343
Burmeister WP, Huber AH, Bjorkman PJ (1994) Crystal structure of the complex of rat neonatal Fc receptor with Fc. Nature 372:379–383
Roopenian DC, Akilesh S (2007) FcRn: the neonatal Fc receptor comes of age. Nat Rev Immunol 7:715–725
Ghetie V, Ward ES (2002) Transcytosis and catabolism of antibody. Immunol Res 25:97–113
Ghetie V, Ward ES (1997) FcRn: the MHC class I-related receptor that is more than an IgG transporter. Immunol Today 18:592–598
Deckert PM (2009) Current constructs and targets in clinical development for antibody-based cancer therapy. Curr Drug Targets 10:158–175
Jarvis B, Faulds D (1999) Etanercept: a review of its use in rheumatoid arthritis. Drugs 57:945–966
Ober RJ, Radu CG, Ghetie V, Ward ES (2001) Differences in promiscuity for antibody-FcRn interactions across species: implications for therapeutic antibodies. Int Immunol 13:1551–1559
Presta LG (2008) Molecular engineering and design of therapeutic antibodies. Curr Opin Immunol 20:460–470
Liu XY, Pop LM, Vitetta ES (2008) Engineering therapeutic monoclonal antibodies. Immunol Rev 222:9–27
Petkova SB, Akilesh S, Sproule TJ, Christianson GJ, Al Khabbaz H, Brown AC et al (2006) Enhanced half-life of genetically engineered human IgG1 antibodies in a humanized FcRn mouse model: potential application in humorally mediated autoimmune disease. Int Immunol 18:1759–1769
Roopenian DC, Christianson GJ, Sproule TJ, Brown AC, Akilesh S, Jung N et al (2003) The MHC class I-like IgG receptor controls perinatal IgG transport, IgG homeostasis, and fate of IgG-Fc-coupled drugs. J Immunol 170:3528–3533
Chaudhury C, Mehnaz S, Robinson JM, Hayton WL, Pearl DK, Roopenian DC et al (2003) The major histocompatibility complex-related Fc receptor for IgG (FcRn) binds albumin and prolongs its lifespan. J Exp Med 197:315–322
Stein C, Kling L, Proetzel G, Roopenian DC, de Angelis MH, Wolf E, Rathkolb B (2012) Clinical chemistry of human FcRn transgenic mice. Mamm Genome 23:259–269
Tam SH, McCarthy SG, Brosnan K, Goldberg KM, Scallon BJ (2013) Correlations between pharmacokinetics of IgG antibodies in primates vs. FcRn-transgenic mice reveal a rodent model with predictive capabilities. MAbs 5:397–405
Proetzel G, Roopenian DC (2014) Humanized FcRn mouse models for evaluating pharmacokinetics of human IgG antibodies. Methods 65:148–153
Proetzel G, Wiles MV, Roopenian DC (2014) Genetically engineered humanized mouse models for preclinical antibody studies. BioDrugs 28:171–180
Anderson CL, Chaudhury C, Kim J, Bronson CL, Wani MA, Mohanty S (2006) Perspective—FcRn transports albumin: relevance to immunology and medicine. Trends Immunol 27:343–348
Osborn BL, Olsen HS, Nardelli B, Murray JH, Zhou JX, Garcia A et al (2002) Pharmacokinetic and pharmacodynamic studies of a human serum albumin-interferon-alpha fusion protein in cynomolgus monkeys. J Pharmacol Exp Ther 303:540–548
Roopenian DC, Low BE, Christianson GJ, Proetzel G, Sproule TJ, Wiles MV (2015) A humanized mouse model to study human albumin metabolism and pharmacokinetics of albumin-based drugs. MAbs 7:344–351
Zalevsky J, Chamberlain AK, Horton HM, Karki S, Leung IW, Sproule TJ, Lazar GA, Roopenian DC, Desjarlais JR (2010) Enhanced antibody half-life improves in vivo activity. Nat Biotechnol 28:157–159
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2016 Springer Science+Business Media New York
About this protocol
Cite this protocol
Roopenian, D.C., Christianson, G.J., Proetzel, G., Sproule, T.J. (2016). Human FcRn Transgenic Mice for Pharmacokinetic Evaluation of Therapeutic Antibodies. In: Proetzel, G., Wiles, M. (eds) Mouse Models for Drug Discovery. Methods in Molecular Biology, vol 1438. Humana Press, New York, NY. https://doi.org/10.1007/978-1-4939-3661-8_6
Download citation
DOI: https://doi.org/10.1007/978-1-4939-3661-8_6
Published:
Publisher Name: Humana Press, New York, NY
Print ISBN: 978-1-4939-3659-5
Online ISBN: 978-1-4939-3661-8
eBook Packages: Springer Protocols